Clinical Trial Detail

NCT ID NCT01973309
Title A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors OncoMed Pharmaceuticals, Inc.
Indications

breast adenocarcinoma

Therapies

Paclitaxel + Vantictumab

Age Groups: adult senior

Additional content available in CKB BOOST